Last reviewed · How we verify
Phase II Study of Irinotecan Plus Capecitabine in Patients With Antracycline and Taxane Pretreated Metastatic Breast Cancer
To evaluate the response rate of capecitabine and irinotecan combination therapy in patients with metastatic breast cancer
Details
| Lead sponsor | National Cancer Center, Korea |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 36 |
| Start date | 2006-08 |
| Completion | 2011-12 |
Conditions
- Breast Cancer Metastatic
Interventions
- Irinotecan plus capecitabine
Primary outcomes
- To evaluate the response rate of capecitabine and irinotecan combination therapy in patients with metastatic breast cancer — 2009
Countries
South Korea